Clinical value of Melanoma Inhibitory Activity in stratifying malignant melanoma patients by Angela Sandru et al.
POSTER PRESENTATION Open Access
Clinical value of Melanoma Inhibitory Activity in
stratifying malignant melanoma patients
Angela Sandru1*, Silviu Voinea1, Eugenia Panaitescu2, Madalina Bolovan3, Adina Stanciu3, Sabin Cinca3,
Alexandru Blidaru1
From Melanoma Bridge Meeting 2014
Naples, Italy. 03-06 December 2014
Background
Malignant melanoma (MM) is a heterogeneous disease,
well-known for its unpredictable clinical course and lack
of response to most systemic therapies. Furthermore in
some parts of the world it has quite an epidemic nature,
with an incidence that has increased steadily in the last
30 years [1]. Therefore the characterization of new tumor
markers that could better suggest the patient outcome
has become a priority for many research centers. Mela-
noma Inhibitory Activity (MIA) is a protein highly
expressed and secreted by malignant melanocytes [1,2],
without being identified in benign melanocytes or other
normal skin cells [3]. More, the induction of MIA synth-
esis seems to be an early event in carcinogenesis, taking
into account that all in situ tumors express it. The objec-
tive of this study was to assess the significance of
increased serum MIA concentration in MM patients with
no metastases at primary diagnoses.
Materials and methods
Between 2008-2012 we have collected 200 blood samples
from 150 patients with non-metastatic MM and 50 healthy
donors. The patients were staged according to TNM clas-
sification 2009 as follows: 28 in stage I, 72 in stage II and
50 in stage III. The blood was withdrawn after the primary
tumor excision and before any other treatment. MIA was
measured by a high sensitivity ELISA method, with a kit
produced by Roche Diagnostics. Using the ROC curve,
MIA cut-off value was set at 9.4 ng/ml [4].
Results We estimated overall survival (OS) and disease
free survival (DFS) for the entire lot and for each stage
separately, according to MIA cut-off level. The length of
follow-up was 44 month, from the moment of MIA
measurement. Univariate Cox regression suggested that
patients with an increased MIA serum concentration
had a three times higher risk of relapse (HR=3.3895)
and death (HR = 2.7597) than patients with values
under the calculated threshold (p=0.000). More impor-
tant is that MIA keeps statistical significance in multi-
variate analyses, predicting risk of death or relapse after
corrections for clinical stage.
Conclusions
In our study, MM patients with a MIA serum concen-
tration above 9.4 ng/ml had a worse DFS (p=0.0109)
and OS (p=0.0009) than patients with values below
9.4 ng/ml. We consider that MIA serum concentration
is a valuable prognostic factor and could become a tool
for selecting patients at risk for developing metastases
rendering them eligible for neoadjuvant treatment.
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